MedAvante is a global provider of centralized expert psychological rating services to the pharmaceutical, biotechnology, and medical device industries. MedAvante is a pioneer in developing a solution for one of the most intractable problems in CNS clinical trials: the high rate of uninformative or failed studies. MedAvante applies unique methods to systematically remove potential sources of bias and variability from the assessment process. By centralizing assessments with expert, standardized, objective, clinical interviewers over MedAvante’s two-way, real-time, high-quality videoconferencing, MedAvante makes subjective assessments of drug efficacy increasingly objective. As a result, sponsors can achieve increased study power and reduced trial-failure rates enabling them to bring more effective CNS drugs to market sooner. MedAvante operates facilities in Hamilton, New Jersey; Los Angeles, California; and Madison, Wisconsin. MedAvante is backed by over $34 million in investor financing including $20 Million in growth financing by Goldman Sachs and Trevi Health Ventures. For more information about MedAvante, visit www.medavante.net.